Tizanidine Tablet
Product Images NDC 71610-455

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Tizanidine (NDC 71610-455). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Aphena Pharma Solutions - Tennessee, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Bottle Label 2 mg (71610 0455 09)

Label for Tizanidine USP 2 mg oral tablets, containing 9000 tablets per bottle. The label indicates storage instructions and is marked for prescription use only. The product is manufactured by Apotex Corp in Weston, Ontario, and repackaged by Aphena Pharma Solutions - Tennessee, LLC in Cookeville, TN. The label includes multiple barcodes and batch information.*

FDA Label Image

Aphena Pharma Solutions (TN)

FDA Label Image

Figure-1.jpg (Figure 1)

A line graph displaying mean tizanidine plasma concentration (ng/mL) over time (hours) after dosing, comparing the profiles of 2 x 4 mg tizanidine tablets and capsules under fasted and fed conditions. The graph shows concentration changes over a 24-hour period post-dosing for four different scenarios.*

FDA Label Image

Figure-2.jpg (Figure 2)

A line graph titled 'Single Dose Study—Mean Change in Muscle Tone from Baseline as Measured by the Ashworth Scale ± 95% Confidence Interval,' depicting the improvement in muscle tone over 6 hours post-dose for 16 mg tizanidine, 8 mg tizanidine, and placebo. The y-axis shows improvement in Ashworth score, with a negative score indicating better muscle tone. The 16 mg dose shows the greatest improvement, followed by 8 mg, then placebo.*

FDA Label Image

Figure-3.jpg (Figure 3)

A line graph showing mean change in muscle tone measured by the Ashworth Scale over a seven-week study. The graph compares tizanidine (mean dose 28.8 mg) and placebo groups at three time points: end of titration (week 3), end of maintenance (week 7), and study endpoint. Negative Ashworth scores indicate improvement in muscle tone from baseline. Error bars represent 95% confidence intervals.*

FDA Label Image

Chemical-structure (Tizanidine Imtb 01)

Chemical structure of tizanidine hydrochloride, depicting its molecular arrangement with chlorine, nitrogen, sulfur atoms, and hydrogen chloride component.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.